Back to results
US 2022/0218831 A1Published application
Degradation of aurora kinase (aurk) by conjugation of aurk inhibitors with e3 ligase ligand
AssigneeNemucore Medical Innovations, Inc.
InventorTimothy Patrick COLEMAN
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds, which act as protein degradation inducing moieties for aurora kinase (AURK). The present application also relates to methods for the targeted degradation of AURK through the use of the compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to AURK which can be utilized in the treatment of disorders modulated by AURK.
Claims32
A compound of Formula X:
- or a pharmaceutically acceptable salt thereof;
- wherein:
- the targeting ligand is a ligand capable of binding to a targeted protein;
- the linker is a group that covalently binds to the targeting ligand and the degron;
- the degron is capable of binding to a ubiquitin ligase;
- and
- n is 1-3.
4 more elements
(canceled)
(canceled)
24-25. (canceled)
27-28. (canceled)
30-37. (canceled)
39-41. (canceled)
(canceled)
Dependencies are inferred from the claim text.